Extraintestinal manifestations of inflammatory bowel disease:Do they influence treatment and outcome?

被引:10
作者
Fernando Tavarela Veloso [1 ]
机构
[1] Department of Gastroenterology, Hospital S. Joao, Faculdade de Medicina, Al. Prof. Hernani Monteiro 4200-319 Porto, Portugal
关键词
Inflammatory bowel disease; Immune-related extraintestinal manifestations; Treatment;
D O I
暂无
中图分类号
R574 [肠疾病];
学科分类号
1002 ; 100201 ;
摘要
Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases that often involve organs other than those of the gastrointestinal tract. Immune-related extraintestinal manifestations (EIMs) are usually related to disease activity, but sometimes may take an independent course. Globally, about one third of patients develop these systemic manifestations. Phenotypic classification shows that certain subsets of patients are more susceptible to developing EIMs, which frequently occur simultaneously in the same patient overlapping joints, skin, mouth, and eyes. The clinical spectrum of these manifestations varies from mild transitory to very severe lesions, sometimes more incapacitating than the intestinal disease itself. The great majority of these EIMs accompany the activity of intestinal disease and patients run a higher risk of a severe clinical course. For most of the inflammatory EIMs, the primary therapeutic target remains the bowel. Early aggressive therapy can minimize severe complications and maintenance treatment has the potential to prevent some devastating consequences.
引用
收藏
页码:2702 / 2707
页数:6
相关论文
共 10 条
[1]  
Extraintestinal manifestations in inflammatory bowel disease[J]. Silvio Danese,Stefano Semeraro,Alfredo Papa,Italia Roberto,Franco Scaldaferri,Giuseppe Fedeli,Giovanni Gasbarrini,Antonio Gasbarrini.World Journal of Gastroenterology. 2005(46)
[2]   Anti-TNF therapies in the management of acute and chronic uveitis [J].
Hale, Sarah ;
Lightman, Sue .
CYTOKINE, 2006, 33 (04) :231-237
[3]   Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease [J].
Freeman, HJ .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 19 (10) :603-606
[4]   Treatment of pyoderma gangrenosum associated with Crohn's disease [J].
Ohmori, T ;
Yamagiwa, A ;
Nakamura, I ;
Nishikawa, K ;
Saniabadi, AR .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (09) :2101-2102
[5]   Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease [J].
Regueiro, M ;
Valentine, J ;
Plevy, S ;
Fleisher, MR ;
Lichtenstein, GR .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (08) :1821-1826
[6]  
Uveitis and erythema nodosum in inflammatory bowel disease: Clinical features and the role of HLA genes[J] . Timothy R. Orchard,C.N. Chua,Tariq Ahmad,Hung Cheng,Kenneth I. Welsh,Derek P. Jewell.Gastroenterology . 2002 (3)
[7]   Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab [J].
Fries, W ;
Giofré, MR ;
Catanoso, M ;
Lo Gullo, R .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (02) :499-500
[8]  
The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study[J] . Charles N Bernstein,James F Blanchard,Patricia Rawsthorne,Nancy Yu.The American Journal of Gastroenterology . 2001 (4)
[9]   Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum [J].
Hohenleutner, U ;
Mohr, VD ;
Michel, S ;
Landthaler, M .
LANCET, 1997, 350 (9093) :1748-1748
[10]  
Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. M. Stone,D. Salonen,M. Lax. The Journal of Rheumatology . 2001